Abstract:Abstract Varied therapeutic responses were observed among cancer patients receiving the same treatment regimen, highlighting the challenge of identifying patients most likely to benefit from a given therapy. Here, we present an artificial intelligence-based approach, called CDK4/6 inhibitor Response Model (CRM), to address the complexity of predicting patient responses to treatment by a certain clinical scene on CDK4/6 inhibitors (CDK4/6i). To train the CRM, we transformed the genomic data of 980 breast cancer patients from the TCGA database into activity profiles of signaling pathways (APSP) by utilizing the modified Damage Assessment of Genomic Mutations (DAGM) algorithm. A scoring model was then established by random forest algorithm to classify the HR+/HER2- and HR-/HER2- breast cancer molecular subtypes by the differential APSP features between the two, which reasonably reflected the potential role played by CDK4/6 molecules in HR+/HER2- breast cancer cells. The effectiveness of CRM was then tested in a separate local patient cohort (n = 343) in Guangdong, China. Twin in-silico clinical trials (ICT) of previously disclosed clinical trials (NCT02246621, NCT02079636, NCT03155997, NCT02513394, NCT02675231) were performed to demonstrate the potential of CRM in generating concerted results as the real-world clinical outcomes. The CRM displayed high precision in classifying HR+/HER2- and HR-/HER2- breast cancer patients in TCGA (AUC=0.9956) and local patient cohorts (AUC=0.9795). Significantly, the scores were distinct (p = 0.025) between CDK4/6i-treated patients with different responses. Breast cancer patients from different subtypes were grouped into five distinct populations based on the scores assigned by the CRM. From twin ICT, the CRM scores reflected the differential responses of patient groups to CDK4/6i-based therapies. Thus, the CRM score showed not only a robust association with clinically observed CDK4/6i responses but also heterogenetic responses across subtypes. More than half of HR+/HER2+ patients may benefit from CDK4/6i-based treatment. The CRM empowered us to conduct ICT on different types of cancer patients responding to CDK4/6i-based therapies. We have discovered 131 subtypes of tumors that should respond to CDK4/6i-based therapies. Finally, one of our IIT demonstrated that chordoma patients, the only go-to treatment option is surgery, greatly responded to CDK4/6i treatment. Citation Format: Mei Yang, Yuhan Liu, Yi-Ching Hsueh, Qiangzu Zhang, Yanhui Fan, Juntao Xu, Min Huang, Xu Li, Su Chen, Jianfei Yang, Gang Niu. Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr LB_B19.

A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib

Abstract LB_B19: Utilizing genome-informed modeling to assess CDK4/6 inhibitor response in breast cancer patients, simulate clinical trials, and result in novel CDK4/6 inhibitor treatment for chordoma patients

Clinical-proteomic classification and precision treatment strategy of chordoma

Proteogenomic characterization of skull-base chordoma

A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma

1228 Comprehensive T-cell Profiling in Chordomas: Single-cell RNA-Seq and TCR Profiling Analysis Uncover Antitumor and Exhaustion Phenotypes for Targeted Immunotherapies

Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review

Activity of pemetrexed in pre-clinical chordoma models and humans

Gene expression profiling identifies two chordoma subtypes associated with distinct molecular mechanisms and clinical outcomes

Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target

Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas

Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma

Genomic profiles and clinical presentation of chordoma

JS07.4.A REGIONAL B-CELL MEDIATED IMMUNOSUPPRESSION IDENTIFIED THROUGH SPATIAL AND SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF CHORDOMA

Whole Genome Sequencing of Skull-Base Chordoma Reveals Genomic Alterations Associated with Recurrence and Chordoma-Specific Survival

A Brief Review of Chordomas: Pathogenesis, Prognostic Factors and Therapeutic Targets.

The role of systemic therapy in advanced skull base chordomas: overview of the current state and the MD Anderson protocol

The embryonic transcription factor Brachyury confers chordoma chemoresistance via upregulating CA9

Abstract B021: Assessing replication stress as an actionable therapeutic opportunity in chordoma